Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 2746 AL 2760

Reply: "Enhancing Parkinson's Disease Research: Recommendations for Addressing Genetic and Environmental Influences in Family History Studies"

Arienti F, Monfrini E, Di Fonzo A.

Mov Disord Clin Pract. 2025 Jun;12(6):887-888. doi: 10.1002/mdc3.70034. Epub 2025 Apr 2.

Synaptic Function and Dysfunction: New Frontiers in CNS Disorders

Aslan FS, Akdag MB, Doganyigit Z, Okan A, Shaikh MF, Akyuz E.

J Neurosci Res. 2025 Apr;103(4):e70033. doi: 10.1002/jnr.70033.

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review

West J, Li M, Wong S, Le GH, Teopiz KM, Valentino K, Dri CE, McIntyre RS.

Neurol Ther. 2025 Aug;14(4):1157-1166. doi: 10.1007/s40120-025-00724-y. Epub 2025 Apr 2.

Effect of the Yon PD App on the Management of Self-Care in People With Parkinson Disease: Randomized Controlled Trial

Lee J, Yoo S, Kim Y, Kim E, Park H, Sohn YH, Kim YJ, Chung SJ, Baik K, Kim K, Yoo JH.

J Med Internet Res. 2025 Apr 2;27:e62822. doi: 10.2196/62822.

Bibliometric and graphical analysis of ferroptosis and aging research: Trends, gaps, and future directions

Cao S, Pang Y, Wei Y, Wang D, Xiong A, Yan J, Zeng H.

Pathol Res Pract. 2025 May;269:155949. doi: 10.1016/j.prp.2025.155949. Epub 2025 Mar 28.

The third wheel or the game changer? How AI could team up with neurologists in Parkinson's care

Malaguti MC, Gios L, Jurman G.

Parkinsonism Relat Disord. 2025 May;134:107797. doi: 10.1016/j.parkreldis.2025.107797. Epub 2025 Mar 28.

Targeting mitochondria-regulated ferroptosis: A new frontier in Parkinson's disease therapy

Wang W, Thomas ER, Xiao R, Chen T, Guo Q, Liu K, Yang Y, Li X.

Neuropharmacology. 2025 Aug 15;274:110439. doi: 10.1016/j.neuropharm.2025.110439. Epub 2025 Mar 31.

Systematic review and consensus conceptual model of meaningful symptoms and functional impacts in early Parkinson's Disease

Mammen JR, Adams JL, Mangrum R, Xiao Y, Barbosa W, Tyo M, Redmond C, Carter C, Cifelli K, Cifelli R, Maruzo H, Meeker J, Shultz G, Thomas C, Bale C, Davies E, Kopil CM, Marras C, Mestre T, Morel T, Simuni T, Stebbins GT, Weintraub D, Stephenson D.

NPJ Parkinsons Dis. 2025 Apr 3;11(1):65. doi: 10.1038/s41531-025-00907-2.

Nootropic foods in neurodegenerative diseases: mechanisms, challenges, and future

Nguyen LAM, Simons CW, Thomas R.

Transl Neurodegener. 2025 Apr 3;14(1):17. doi: 10.1186/s40035-025-00476-7.

I-Beam Sign in Progressive Supranuclear Palsy

Manorenj S, Chillapuram S.

Neurol India. 2025 Mar 1;73(2):330-331. doi: 10.4103/neurol-india.Neurol-India-D-24-00101. Epub 2025 Apr 3.

Erratum to "Decline of olfactory function in Parkinson's disease: A ten-year longitudinal study"

J Parkinsons Dis. 2025 May;15(3):673. doi: 10.1177/1877718X251333920. Epub 2025 Apr 2.

Running into Trouble: The Problem of Overexercise in Parkinson's Disease (in some)

Boon LI, Batla A, Bhatia KP.

Mov Disord Clin Pract. 2025 Jul;12(7):1031-1032. doi: 10.1002/mdc3.70066. Epub 2025 Apr 3.

Simultaneous Nonmotor Symptoms Do Not Affect General Validity but Interpretation of the Parkinson's Disease Motor Diary

Andersson H, Bremer A, Gandor F, Ebersbach G, Löhle M, Odin P, Storch A.

Mov Disord Clin Pract. 2025 Jul;12(7):979-984. doi: 10.1002/mdc3.70061. Epub 2025 Apr 3.

Skin pathology in ALS: Diagnostic implications and biomarker potential

Gao Y, Lu Y, Chen R, Zhao S, Liu J, Zhang S, Bai X, Zhang J.

Biomol Biomed. 2025 Apr 2;26(3):368-376. doi: 10.17305/bb.2025.12100.

Biological kinematics: a detailed review of the velocity-curvature power law calculation

Fraser DS, Di Luca M, Cook JL.

Exp Brain Res. 2025 Apr 3;243(5):107. doi: 10.1007/s00221-025-07065-0.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias